Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 8/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | SPHK1 | Q9NYA1 | 3/20 | 0.32 |
| ▸ | MMP2 | P08253 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MMP3 | P08254 | 1/20 | 0.31 |
| ▸ | BMP1 | P13497 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5761943 | 1.00 | FKBP1A (0.41) | FKBP1ASMN1; SMN2HSD17B10SPHK1MMP2 | |
| SCHEMBL5416055 | 0.93 | FKBP1A (0.41) | FKBP1ASMN1; SMN2HSD17B10KMT2APOLB | |
| SCHEMBL14502974 | 0.93 | FKBP1A (0.41) | FKBP1ASMN1; SMN2HSD17B10KMT2APOLB | |
| SCHEMBL6430228 | 0.83 | SMN1; SMN2 (0.34) | FKBP1ASMN1; SMN2MMP2KMT2ABMP1 | |
| SCHEMBL6430229 | 0.83 | SMN1; SMN2 (0.34) | FKBP1ASMN1; SMN2MMP2KMT2ABMP1 | |
| SCHEMBL5408295 | 0.80 | BMP1 (0.37) | FKBP1ABMP1 | |
| SCHEMBL5408291 | 0.80 | BMP1 (0.37) | FKBP1ABMP1 | |
| SCHEMBL5416058 | 0.79 | BACE1 (0.31) | — | |
| SCHEMBL5421943 | 0.78 | MMP2 (0.39) | SMN1; SMN2MMP2KMT2AMMP3BMP1 | |
| SCHEMBL5421945 | 0.78 | MMP2 (0.39) | SMN1; SMN2MMP2KMT2AMMP3BMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1343771-B1 | 3-OX(ADI)AZOLYLPROPANOHYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS | PFIZER LTD (GB) | 2006-04-12 | — | — | EP | disclosed |
| US-6716861-B2 | HETEROCYCLIC 1,2,4-OXADIAZOLE OR OXAZOLE RING CONTAINING PROPANOHYDROXAMIC ACIDS USEFUL AS ANTISCARRING AGENT | PFIZER, INC. | 2004-04-06 | — | — | US | disclosed |
| EP-1343771-A1 | 3-OX(ADI)AZOLYLPROPANOHYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS | Pfizer Limited (GB) | 2003-09-17 | — | — | EP | disclosed |
| US-20020151535-A1 | 3-ox(adi) azolylpropanohydroxamic acids useful as procollagen C- Proteinase inhibitors | PFIZER, INC | 2002-10-17 | — | — | US | disclosed |
| WO-2002050046-A1 | 3-OX(ADI)AZOLYLPROPANOHYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS | PFIZER LIMITED (GB) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151535-A1 | 3-ox(adi) azolylpropanohydroxamic acids useful as procollagen C- Proteinase inhibitors | ALPI, TIMP3, MMP1 | FKBP1A 283/4885SMN1; SMN2 4510/4885HSD17B10 515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.